12:00 AM
 | 
Jul 17, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Progenics preclinical data

PGNX said that the combination of PRO 542 and T-20, a gp41 peptide analog viral fusion inhibitor developed by Trimeris Inc. (TRMS, Durham,...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >